At ROVI we don't believe in borders

Since its foundation, ROVI has had a clearly international outlook. Currently we are present in over 100 countries, as a result of implementing a strategy that began in 1998 and has been oriented towards growth and internationalisation of our low-molecular-weight heparins (LMWH).

Reaching more countries and more people


ROVI markets different drugs all over the world. Bemiparin is one of its main drivers and has the most extensive international track record, present in more than 60 countries.


Our enoxaparin biosimilar, which is now present in 38 countries, is boosting ROVI's international presence.